1A-O1-1640 PDF
プロテオミクスの新薬創成への応用
Mass spectrometry (MS)-based proteomics has been emerged in late 1980s and markedly advanced through 1990s and 2000s. Currently it is not uncommon to see reports using proteomics in prestigious biology/medical journals. We have tried to leverage this valuable proteomics technology into the process of creating innovative drugs for more than 10 years. Thus, we will present three recent examples of proteomics applications in pharmaceutical industry; 1) protein-protein interaction analysis to investigate mechanism-of-action of possible drug targets, 2) establishment of quantitation of highly homologous isozymes in plasma samples by affinity purification coupled with multiple reaction monitoring (MRM)-MS to confirm protein induction hypothesis by drug administration in a clinical trial, and 3) improvement of proteomic correlation profiling technology and identification of a drug-metabolizing enzyme from human tissue. We will also discuss significance of MS-based proteomics to identify predictive biomarkers for personalized medicine.